News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2024-03-18 11:21:6 pm Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone SeekingAlpha
2024-03-18 8:2:0 am Immuneering (IMRX) Plummets 71% in One Week: Here's Why Zacks
2024-03-14 4:0:0 am Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors GlobeNewswire
2024-03-12 5:0:0 am Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors GlobeNewswire
2024-03-11 5:0:0 am Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors GlobeNewswire
2024-03-05 2:0:0 pm Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 GlobeNewswire
2024-03-04 5:0:0 am Immuneering to Participate in the Cowen 44th Annual Health Care Conference GlobeNewswire
2024-03-03 4:1:35 pm Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results GuruFocus.com
2024-03-01 5:0:0 am Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates GlobeNewswire
   

Please consider a small donation if you think this website provides you with relevant information